<DOC>
	<DOCNO>NCT02654717</DOCNO>
	<brief_summary>The purpose study see well DFD-07 work treat actinic keratosis face scalp 8 week treatment . The study also look unwanted effect study drug .</brief_summary>
	<brief_title>Eight Week Study Treatment With DFD-07 Actinic Keratosis Face Scalp</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>To eligible study , patient fulfil follow criterion Visit 1 : 1 . Written inform consent sign date prior study related procedure initiation wash period 2 . Skin type I , II III accord Fitzpatrick 3 . 58 Actinic Keratosis ( AK ) mild moderate grade lesion approximately 25 cm2 region scalp , forehead face nonhypertrophic nonhyperkeratotic 4 . 18 year age old 5 . Female patient childbearing potential must agree use contraception study include abstinence secondary contraceptive option patient become sexually active . All woman childbearing potential must negative urine pregnancy test ( test must sensitivity least 25 IU/ML human chorionic gonadotropin ) Baseline Visit . A female consider childbearing potential unless premenarche , postmenopausal menses least 12 month surgically sterile . Reliable method contraception hormonal method intrauterine device use least 90 day prior Baseline Visit barrier method plus spermicide use least 14 day prior Baseline Visit partner vasectomy least 3 month prior Baseline Visit . 6 . ≥ 60 day washout prohibited medication : Masoprocol 5Fluorouracil Cyclosporine Retinoids Trichloroacetic Acid/Lactic Acid Peel 50 % Glycolic Acid Peel Topical systemic diclofenac , celecoxib nonsterioda antiinflammatory drug ( however daily lowdose aspirin allow , long patient stable dose , ≤ 100 mg day , 60 day prior start study . ) Note : Patients may use acetaminophen/paracetamol need Photodynamic therapy Topical systemic immunomodulating agent include : Systemic , topical intralesional interferon Imiquimod ( Aldara , Zyclara ) Topical ingenol mebutate ( Picato ) Topical tacrolimus Topical pimecrolimus Sirolimus Cyclosporin Intralesional Bacillus CalmetteGuerin ( BCG ) Topical coal tar product Topical systemic corticosteroid Patients fulfil one follow criterion , eligible study : 1 . Known suspected hypersensitivity nonsteroidal antiinflammatory drug ( NSAID ) component formulation study medication 2 . Clinical evidence severe , uncontrolled autoimmune , cardiovascular , gastrointestinal , hematological , hepatic , neurologic , pulmonary renal disease . 3 . Significant history ( within past year ) alcohol drug abuse 4 . Participation clinical research study within 60 day Baseline Visit . 5 . Pregnancy , lactation plan become pregnant 6 . Concomitant use cosmetic topical drug product near select treatment area . However , use topical sunscreen allow . 7 . Cosmetic therapeutic procedure ( e.g . laser , peeling , photodynamic therapy ) within 2 week within 2 cm select treatment area . 8 . Other skin condition within select treatment area ( e.g . rosacea , psoriasis , atopic dermatitis , eczema , basal squamous cell carcinoma albinism ) 9 . Use sun lamp tan bed booths 14 day prior Baseline Visit plan use study . 10 . Any systemic cancer therapy within 6 month Baseline Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>